(Q45880196)

17 December 2017

title

Case Report: Successful Use of Antifibrinolytic Therapy in Acquired Factor VIII Deficiency (English)

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

14 October 2022

author name string

R. B. Lalwani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605170

14 October 2022

R. B. Stricker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1605170

14 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

17 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0002962915356858?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

https://api.elsevier.com/content/article/PII:S0002962915356858?httpAccept=text/plain

14 October 2022

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

American Journal of the Medical Sciences

14 October 2022

published in

1 reference

17 December 2017

volume

303

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

398-401

1 reference

17 December 2017

Factor VIII inhibitors: a clinical overview

cites work

2

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Management of patients with factor VIII inhibitors

14 October 2022

3

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

An idiopathic factor VIII anticoagulant: resolution following plasmapheresis and cytotoxic therapy

14 October 2022

10

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

14 October 2022

11

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

14 October 2022

12

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Desmopressin therapy in patients with acquired factor VIII inhibitors

14 October 2022

14

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors

14 October 2022

15

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Management of dental extractions in two hemophilia A patients with factor VIII inhibitor

14 October 2022

17

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Epsilon-Aminocaproic Acid (EACA)

14 October 2022

18

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Characterization of an extremely large, ligand-induced conformational change in plasminogen

14 October 2022

19

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase

14 October 2022

20

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Epsilon-Aminocaproic Acid Therapy for Dental Extractions in Haemophilia and Christmas Disease: A Double Blind Controlled Trial

14 October 2022

21

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature

14 October 2022

25

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Epsilon Aminocaproic Acid — A Dangerous Weapon

14 October 2022

26

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid

14 October 2022

27

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Use of epsilon aminocaproic acid in protracted bleeding from polycystic kidneys: a case report

14 October 2022

28

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract

14 October 2022

29

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Clinical application of inhibitors of fibrinolysis

14 October 2022

31

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation

14 October 2022

32

1 reference

https://api.crossref.org/works/10.1097/00000441-199206000-00009

14 October 2022

Identifiers

1 reference

17 December 2017

1 reference

17 December 2017